Quick Answer
Inmune Bio, Inc. reported Cash and Equivalents of $24.75 million for fiscal year 2025.
Inmune Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $24.75M | +18.3% |
| 2024 | $20.92M | -41.6% |
| 2023 | $35.85M | -31.3% |
| 2022 | $52.15M | -30.3% |
| 2021 | $74.81M | +240.6% |
| 2020 | $21.97M | +214.0% |
| 2019 | $7.00M | +3657.2% |
| 2018 | $186.2K | -86.4% |
| 2017 | $1.37M | +867.6% |
| 2016 | $141.7K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.73M | -17.3% | -16.9% |
| June 30, 2025 | $33.37M | +7.4% | +72.6% |
| March 31, 2025 | $19.34M | -25.6% | -7.6% |
| December 31, 2024 | $20.92M | -41.6% | -37.6% |
| September 30, 2024 | $33.55M | -19.8% | +8.0% |
| June 30, 2024 | $31.07M | -35.0% | +19.5% |
| March 31, 2024 | $26.00M | -49.0% | -27.5% |
| December 31, 2023 | $35.85M | -31.3% | -14.3% |
- Inmune Bio, Inc. showed an increase of +18.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Inmune Bio, Inc.’s cash and equivalents has grown by 17372.2% (from $141.7 thousand to $24.75 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: